Goldman Sachs' decision to maintain a Neutral rating for BioXcel Therapeutics indicates that they do not expect significant short-term price movement. However, the lowered price target from $28 to $25 may have a slight negative impact on investor sentiment. The stock is currently down 4.76% at $18.40, but the new price target still represents a potential 35.87% increase from the current share price. Overall, the impact on BTAI's stock price in the short term is expected to be neutral.